Intra-Organ Delivery of Nanotherapeutics for Organ Transplantation,ACS Nano

当前位置： X-MOL 学术 › ACS Nano › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Intra-Organ Delivery of Nanotherapeutics for Organ Transplantation
ACS Nano ( IF 15.8 ) Pub Date : 2021-10-29 , DOI: 10.1021/acsnano.1c04707
Bilal Hussain , Vivek Kasinath , Joren C Madsen ₁ , Jonathan Bromberg ₂ , Stefan G Tullius , Reza Abdi

Affiliation

Targeted delivery of therapeutics through the use of nanoparticles (NPs) has emerged as a promising method that increases their efficacy and reduces their side effects. NPs can be tailored to localize to selective tissues through conjugation to ligands that bind cell-specific receptors. Although the vast majority of nanodelivery platforms have focused on cancer therapy, efforts have begun to introduce nanotherapeutics to the fields of immunology as well as transplantation. In this review, we provide an overview from a clinician’s perspective of current nanotherapeutic strategies to treat solid organ transplants with NPs during the time interval between organ harvest from the donor and placement into the recipient, an innovative technology that can provide major benefits to transplant patients. The use of ex vivo normothermic machine perfusion (NMP), which is associated with preserving the function of the organ following transplantation, also provides an ideal opportunity for a localized, sustained, and controlled delivery of nanotherapeutics to the organ during this critical time period. Here, we summarize previous endeavors to improve transplantation outcomes by treating the organ with NPs prior to placement in the recipient. Investigations in this burgeoning field of research are promising, but more extensive studies are needed to overcome the physiological challenges to achieving effective nanotherapeutic delivery to transplanted organs discussed in this review.

中文翻译：

用于器官移植的纳米治疗药物的器官内递送

通过使用纳米粒子 (NPs) 靶向递送治疗剂已成为一种有前途的方法，可提高其疗效并减少其副作用。通过与结合细胞特异性受体的配体缀合，可以对 NP 进行定制以定位到选择性组织。尽管绝大多数纳米递送平台都专注于癌症治疗，但已经开始努力将纳米治疗引入免疫学和移植领域。在这篇综述中，我们从临床医生的角度概述了当前纳米治疗策略，在从供体器官采集到放置到受体体内之间的时间间隔内使用 NPs 治疗实体器官移植，这是一项可以为移植患者带来重大益处的创新技术. 使用离体常温机器灌注 (NMP) 与移植后器官功能的保持有关，也为在此关键时期内将纳米治疗药物局部、持续和受控地输送到器官提供了理想的机会。在这里，我们总结了以前通过在植入接受者之前用 NPs 处理器官来改善移植结果的努力。对这个新兴研究领域的调查很有希望，但需要更广泛的研究来克服生理学挑战，以实现本综述中讨论的向移植器官有效递送纳米治疗药物。

更新日期：2021-11-23

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南